Increased PT and Increased PTT
Coumadin therapy in the therapeutic or supratherapeutic range
Moderate to severe vitamin K deficiency
Treatment with high doses of heparin or low molecular weight heparin
Treatment with direct thrombin inhibitors, such as hirudin or related compounds (i.e., lepirudin, refludan) or argatroban
Moderate to severe DIC
Moderate to severe liver disease
A lupus inhibitor with an associated decrease in factor II or a lupus inhibitor strong enough to increase PT, as well as PTT
Suggested Additional Lab Testing
To assess the possibility of DIC, get D-dimer levels.
If D-dimers are elevated, measure platelet count and fibrinogen level.
Test for factors II, V, VII, and X to assess a PT prolongation.
Test for factors VIII, IX, XI, and XII to assess a PTT prolongation.
In liver disease, all the factors can be low, except factor VIII, which tends to become elevated because it can be synthesized outside the liver.
Obtain liver function tests, especially serum albumin, to determine if the PT and PTT abnormalities could be associated with decreased production of coagulation factors by the liver.
Get a value for PTT after the sample is treated with an enzyme that degrades heparin.
If PTT and PT normalize after removal of heparin from the sample, PT and PTT elevations are most likely associated with heparin or low molecular weight heparin treatment.
Do a lupus inhibitor test if there is no explanation for the PT and PTT prolongations from the previously mentioned tests.
Factor II level may be useful to accompany the lupus anticoagulant test, because some lupus anticoagulant patients have a low factor II, leading to a prolonged PT.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
The Cardiology Advisor Articles
- The Mounting Evidence Against Electronic Cigarette Use
- Entresto Significantly Improves Physical, Social Activity in Heart Failure Patients
- Nonpsychotic Cannabinoids in Hypertension: Benefits and Harms
- Oxygen Therapy in Acute MI Not Associated With Clinical Benefit
- ACC and AHA Release 2018 Quality Measures for Cardiac Rehabilitation
- FDA Announces New Initiative Aimed at Stopping Youth Use of E-Cigarettes
- Why is #MeToo Missing From Medical Schools?
- Controlling High Blood Pressure Could Prevent Dementia
- AHA: Assessment and Promotion of Physical Activity for CVD Prevention
- Benefits of Targeted Pharmacologic Therapy in PAH and Distal CTEPH